Press coverage about Infinity Pharmaceuticals (NASDAQ:INFI) has been trending somewhat positive on Saturday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Infinity Pharmaceuticals earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.8352007699599 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, ValuEngine upgraded Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 6th.
Shares of Infinity Pharmaceuticals (INFI) traded up 5.79% on Friday, hitting $1.28. The stock had a trading volume of 2,377,582 shares. Infinity Pharmaceuticals has a one year low of $0.84 and a one year high of $3.84. The stock’s market cap is $64.88 million. The company’s 50 day moving average is $1.16 and its 200 day moving average is $1.87.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.12). During the same period last year, the firm earned $1.05 EPS. Equities research analysts predict that Infinity Pharmaceuticals will post ($0.92) EPS for the current fiscal year.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.